Aptose Acquires China Rights to Leukemia Candidate in $125 Million Agreement
publication date: Jun 15, 2018
Aptose Biosciences of San Diego has added greater China to its in-licensing deal for a leukemia candidate discovered by Korea's CrystalGenomics. Aptose paid $3 million upfront and agreed to additional milestones along with a single-digit royalty on sales, totaling up to $125 million. CG-806 is a novel pre-clinical small molecule treatment for acute myeloid leukemia. In 2016, Aptose signed an $303 million option agreement for CG-806, excluding China and Korea. Last month, Aptose exercised that option ahead of schedule. More details....
Stock Symbols: (NSDQ: APTO; TSX: APS) (KOSDAQ: 083790)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.